1. [Kinase inhibitors].
- Author
-
Yamori T and Kong D
- Subjects
- Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Benzamides, Bevacizumab, Biomarkers, Tumor, Drug Design, ErbB Receptors antagonists & inhibitors, Fusion Proteins, bcr-abl antagonists & inhibitors, Genes, ras genetics, Humans, Imatinib Mesylate, Mutation, Neoplasms diagnosis, Neoplasms etiology, Phosphoinositide-3 Kinase Inhibitors, Piperazines, Protein-Tyrosine Kinases antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics, Pyrimidines, Rituximab, Signal Transduction, Neoplasms drug therapy, Neoplasms enzymology, Phosphotransferases physiology, Protein Kinase Inhibitors
- Abstract
Various kinases phosphorylate their substrates and thereby switch on or off their functions. Dysregulation of kinases that regulate cell growth signals induces carcinogenesis or malignant phenotypes in cancer. Therefore, kinases are considered to be most promising therapeutic targets in cancer treatment, and the development of kinase inhibitors has been the most hot area. In this article, the present status and the perspective of kinase inhibitors were described.
- Published
- 2010